Gamida Cell Reports Fourth Quarter and Full-Year 2023 Financial Results and Provides Company Update
BOSTON, March 27, 2024 (GLOBE NEWSWIRE) -- Gamida Cell Ltd. (Nasdaq: GMDA), a cell therapy pioneer working to turn cells into powerful therapeutics, today provided a business update and reported financial results for the fourth quarter and full year ended December 31, 2023.
- (Nasdaq: GMDA), a cell therapy pioneer working to turn cells into powerful therapeutics, today provided a business update and reported financial results for the fourth quarter and full year ended December 31, 2023.
- Gamida Cell will become a private company, wholly owned by Highbridge, and the company’s outstanding ordinary shares are expected to be canceled.
- The company has confirmed coverage with payers who cover more than 90% of commercial lives, exceeding the 2023 goal of 70%.
- The full year Net Revenue included $1.1 million of net review for the fourth quarter of 2023.